ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning

被引：0
|
作者：
Bryan J. Schneider
Andrew C. Chang
机构：
[1] University of Michigan,Department of Internal Medicine
[2] University of Michigan,Department of Surgery
来源：
Annals of Surgical Oncology | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This ASO perspective reviews the findings of a randomized placebo-controlled, clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma, reported recently by the Checkmate 577 investigators. The use of postoperative immunotherapy represents a significant paradigm shift for managing patients who have had limited evidence-based treatment options after completing neoadjuvant chemoradiation followed by resection for these aggressive malignancies.
引用
下载
收藏
页码：2735 / 2738
页数：3
相关论文
共 50 条
  • [11] NUMBER NEEDED TO TREAT ANALYSIS OF NIVOLUMAB VERSUS SURVEILLANCE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC)
    Singh, P.
    Kassahun, S.
    Toor, K.
    Kim, I
    Kakehi, S.
    Estella-Perez, E.
    Venkatachalam, M.
    VALUE IN HEALTH, 2022, 25 (07) : S387 - S387
  • [12] Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small
    Daniele Mengato
    Marco Chiumente
    Andrea Messori
    Journal of Gastrointestinal Cancer, 2023, 54 : 9 - 10
  • [13] Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small
    Mengato, Daniele
    Chiumente, Marco
    Messori, Andrea
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (01) : 9 - 10
  • [14] HEALTHCARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER OR GASTROESOPHAGEAL JUNCTION CANCER (EC/GEJC) RECEIVING ADJUVANT NIVOLUMAB TREATMENT VERSUS PLACEBO
    Lawrance, R.
    Singh, P.
    Leso, A.
    Moreno-Koehler, A.
    Padilla, B.
    Sun, X.
    Taylor, F.
    Blum, S.
    VALUE IN HEALTH, 2021, 24 : S34 - S35
  • [15] EXPOSURE RESPONSE ANALYSES OF NIVOLUMAB AS ADJUVANT TREATMENT FOR PATIENTS WITH ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER (CHECKMATE 577).
    Zhao, Y.
    Tsujimoto, A.
    Ide, T.
    Zhu, L.
    Zhang, J.
    Feng, Y.
    Gao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S60 - S60
  • [16] Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
    Kelly, R. J.
    Ajani, J. A.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J. L.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Zhang, J.
    Zhu, L.
    Lei, M.
    Kondo, K.
    Cleary, J. M.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1193 - S1194
  • [17] DEVELOPING A COST-EFFECTIVENESS ANALYSIS FOR NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN THE ABSENCE OF OVERALL SURVIVAL DATA
    Amadi, A.
    Toor, K.
    Keeney, E.
    Thom, H.
    Singh, P.
    Kim, I
    Venkatachalam, M.
    VALUE IN HEALTH, 2022, 25 (01) : S67 - S67
  • [18] Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
    Kelly, R.
    Moehler, M.
    Ajani, J.
    Yao, J.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Yang, Y.
    Zhang, J.
    Novosiadly, R.
    Cleary, J.
    Lei, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S183 - S183
  • [19] Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577
    Zander, T.
    Kelly, R. J.
    Ajani, J. A.
    Kuzdzal, J.
    van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Zhang, J.
    Soleymani, S.
    Lei, M.
    Singh, P.
    Cleary, J. M.
    Moehler, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 80 - 81
  • [20] Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
    Moehler, M.
    Ajani, J. A.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Zhang, J.
    Soleymani, S.
    Lei, M.
    Kondo, K.
    Cleary, J.
    Kelly, R. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1045 - S1046
12345